Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMobeus I&g Regulatory News (MIX)

  • There is currently no data for MIX

Interim Management Statement

9 Nov 2022 15:00

RNS Number : 8763F
Mobeus Income & Growth VCT PLC
09 November 2022
 

 

Mobeus Income & Growth VCT plc

("the Company")

LEI: 213800HKOSEVWS7YPH79

 

INTERIM MANAGEMENT STATEMENT

For the quarter ended 30 September 2022

 

Mobeus Income & Growth VCT plc presents an Interim Management Statement for the quarter ended 30 September 2022. The statement also includes relevant financial information between the end of the period and the date of this statement.

 

NET ASSET VALUE AND TOTAL RETURN PER SHARE

At 30 September 2022

(unaudited)

At 30 June 2022

(unaudited)

Net assets attributable to shareholders

£93.36 million

£103.56 million

Shares in issue

136,965,856

137,080,943

Net asset value (NAV) per share

68.16 pence

75.55 pence

Cumulative dividends paid

152.80 pence

148.80 pence

Cumulative Total return (net asset value basis) per share since inception

220.96 pence

224.35 pence

 

The NAV per share has decreased by 7.39 pence in the quarter (a decrease of 9.8% since 30 June 2022). This decrease arises both from the 4.00 pence per share dividend paid in July 2022 as well as a fall in unrealised valuations. On a total return basis, after adding back the dividend of 4.00 pence per share, the decrease is 4.5%.

 

OFFER FOR SUBSCRIPTION

 

On 17 October 2022, the Company took part in a Joint Offer for Subscription ("Offer") alongside the other Mobeus VCTs seeking to raise an initial amount of £14 million for the Company with an over-allotment facility of £8 million available. Following strong demand for the Offer, the Directors approved the utilisation of the over-allotment facility later on 17 October 2022. As stated in the Prospectus, the first allotment under the Offer in relation to applications accepted for the initial amount is expected on or around 16 November 2022. Accepted applications by the Company for the over-allotment facility will be allotted in January 2023

 

DIVIDEND PAID IN THE PERIOD

 

On 15 July 2022, an interim dividend of 4.00 pence per share in respect of the year ending 31 December 2022 was paid to all Shareholders whose names were on the register on 10 June 2022.

 

A second interim dividend of 4.00 pence per share in respect of the year ending 31 December 2022 was declared on 5 September 2022. This was paid on 7 November 2022 to those Shareholders on the Register of Members on 16 September 2022. Payment of this second interim dividend has reduced NAV per share (shown above) to 64.16 pence and increased cumulative dividends paid to 156.80 pence per share.

 

INVESTMENT ACTIVITY DURING THE PERIOD

 

New Investment during the period

On 9 September 2022, the Company completed a new investment of £0.60 million into Focalpoint Positioning Limited, a navigation and positioning technology company.

 

On 12 September 2022, a new investment of £0.53 million was made into Orri Limited, a provider of specialist eating disorder treatments.

 

Follow-on investments during the period

On 5 July 2022, a follow on investment of £0.78 million was made into Vivacity Labs Limited, an AI and urban traffic control business.

 

On 23 August 2022, a follow on investment of £0.43 million was made into Bleach London Holdings Limited, a hair colourants brand.

 

Loan repayment and other proceeds during the period

The Company received deferred consideration of £0.05 million from Media Business Insight Holdings Limited, an investment realised in a prior quarter.

 

Share buy-backs

On 23 September 2022, the Company purchased 115,087 of its own ordinary shares at a price of 64.17 pence per share.

 

All shares bought back by the Company were subsequently cancelled.

 

 

INVESTMENT ACTIVITY AFTER THE PERIOD END

 

On 21 October 2022, a loan repayment (including premium) from Jablite Holdings Limited of £0.07 million was received.

 

Share buy-backs

 

After the period end, on 10 October 2022, the Company purchased 264,268 of its own ordinary shares at a price of 64.17 pence per share.

 

All shares bought back by the Company were subsequently cancelled.

 

 

Please note that all of the above information is unaudited.

 

Other than as described above, there were no material events during the period and to the date of this announcement.

 

For further information, please contact:

Gresham House Asset Management Limited,

Company Secretary: 020 7382 0999

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFSDFLUEESEIF
Date   Source Headline
18th Jun 202511:15 amRNSChange of Name
9th Jun 202512:30 pmRNSRealisation of investment in Rota Geek Limited
2nd Jun 20257:00 amRNSRealisation of investment in My Tutorweb Limited
1st May 20257:00 amRNSTotal Voting Rights
11th Apr 20252:00 pmRNSIssue of Equity and Total Voting Rights
1st Apr 20257:00 amRNSTransaction in Own Shares and Total Voting Rights
17th Mar 20257:00 amRNSTransaction in own shares and Total Voting Rights
5th Mar 20256:01 pmRNSResult of AGM
5th Mar 20253:55 pmRNSInterim Management Statement
5th Mar 202512:25 pmRNSDividend Declaration
3rd Mar 20252:30 pmRNSTotal Voting Rights and Capital
26th Feb 20254:00 pmRNSNet Asset Value(s)
3rd Feb 20257:00 amRNSTotal Voting Rights
21st Jan 20252:00 pmRNSTransaction in Own Shares and Total Voting Rights
14th Jan 20254:06 pmRNSAnnual Financial Report
2nd Dec 20247:00 amRNSTotal Voting Rights and Capital
28th Oct 20242:05 pmRNSDirector/PDMR Shareholding
28th Oct 20242:00 pmRNSIssue of Equity and Total Voting Rights
15th Oct 202411:15 amRNSOFFER FOR SUBSCRIPTION - UPDATE
2nd Oct 20247:00 amRNSIssue of Equity
26th Sep 20249:00 amRNSTransaction in Own Shares and Total Voting Rights
19th Sep 20241:06 pmRNSHalf-year Report
18th Sep 202410:00 amRNSOffer for Subscription – Update
2nd Sep 20243:15 pmRNSOffer for Subscription – Open for Applications
2nd Sep 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
1st Aug 20247:00 amRNSTotal Voting Rights and Capital
26th Jul 20243:00 pmRNSDirector/PDMR Shareholding
26th Jul 20242:00 pmRNSGENERAL MEETINGS AND MERGER RESULTS
24th Jul 20244:15 pmRNSNet Asset Value(s)
18th Jul 20241:32 pmRNSMERGER UPDATE AND GENERAL MEETINGS
4th Jul 20247:00 amRNSTransaction in Own shares and Total Voting Rights
1st Jul 20249:42 amRNSTotal Voting Rights and Capital
18th Jun 20245:30 pmRNSPROPOSED MERGER AND OFFERS
10th Jun 20244:00 pmRNSMerger Proposals/Intention To Launch Joint Offers
3rd Jun 20247:00 amRNSTotal Voting Rights and Capital
28th May 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
20th May 20245:34 pmRNSResult of Annual General Meeting
20th May 20247:00 amRNSInterim Management Statement
1st May 20247:00 amRNSTotal Voting Rights and Capital
26th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
24th Apr 20247:00 amRNSDividend Declaration
15th Apr 20247:00 amRNSAnnual Financial Report
2nd Apr 20249:30 amRNSTotal Voting Rights and Capital
1st Mar 202411:00 amRNSTotal Voting Rights and Capital
28th Feb 20243:30 pmRNSMerger Discussions
27th Feb 20242:00 pmRNSRealisation of Investment: Master Removers Group
22nd Feb 202411:00 amRNSNet Asset Value(s)
1st Feb 202411:46 amRNSVoting Rights and Capital
2nd Jan 20241:00 pmRNSVoting Rights and Capital
21st Dec 202312:00 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.